12Sep/13

Gilead leaps ahead with FDA app for PI3K cancer killer – FierceBiotech

Gilead leaps ahead with FDA app for PI3K cancer killer
FierceBiotech
As the biotech giant had said was a possibility, Gilead is seeking an early approval for idelalisib to combat indolent cases of non-Hodgkin’s lymphoma (NHL) that fail to respond to rituximab and alkylating-agent chemotherapies. Foster City, CA-based
Gilead Seeks FDA Approval for IdelalisibYahoo! News
Idelalisib NDA Submitted for Indolent Non-Hodgkin’s LymphomaMonthly Prescribing Reference
Gilead Submits NDA for IdelalisibDrug Discovery & Development
PharmaTimes
all 8 news articles »
11Sep/13

Reports from Red Cross Hospital Highlight Recent Findings in Lymphoma – HispanicBusiness.com

Reports from Red Cross Hospital Highlight Recent Findings in Lymphoma
HispanicBusiness.com
According to news reporting originating in Shizuoka, Japan , by NewsRx journalists, research stated, “We retrospectively investigated high-dose chemotherapy (HDT) plus rituximab followed by autologous stem cell transplantation (ASCT) for patients with 

11Sep/13

« Mêmes chances » campaign : Quebeckers ask the Minister of Health and … – Canada NewsWire (press release)

« Mêmes chances » campaign : Quebeckers ask the Minister of Health and
Canada NewsWire (press release)
Remember that this treatment, in combination with rituximab, is accessible to the majority of other Canadian provinces and prolongs survival without disease progression for patients with indolent non-Hodgkin Lymphoma (iNHL) from 31.2 months to 69.5 

10Sep/13

AbbVie Inc (ABBV): AbbVie's CEO Presents at Morgan Stanley Healthcare … – Seeking Alpha

AbbVie Inc (ABBV): AbbVie’s CEO Presents at Morgan Stanley Healthcare
Seeking Alpha
In addition to that we have the number of other products that will get important data read-outs in 2014 Daclizumab our product for the treatment of MS. We’ve completed enrollment in our second pivotal trail there, and we expect to get result of that

09Sep/13

Biogen Idec Inc (BIIB): Biogen Idec's CEO Presents at Morgan Stanley … – Seeking Alpha

Biogen Idec Inc (BIIB): Biogen Idec’s CEO Presents at Morgan Stanley
Seeking Alpha
We have daclizumab in 2014 and then actually a series of Phase 1, Phase 2 readouts that are pretty important, that we can talk about some more. I think that I started with the commercial phase, but if you look at the trajectory, the journey that the